Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Coricidin is a brand of over-the-counter combination medications used to treat symptoms associated with the common cold, influenza, and allergies. Originally introduced by Schering-Plough in 1949 and currently owned by Bayer, the product line is most distinguished by its "HBP" (High Blood Pressure) formulations. These versions are specifically designed for patients with hypertension as they omit decongestants like pseudoephedrine or phenylephrine, which are known to increase blood pressure. The typical active ingredients include chlorpheniramine maleate (a first-generation antihistamine), dextromethorphan hydrobromide (a cough suppressant), and acetaminophen (an analgesic and antipyretic). Together, these components provide relief from sneezing, runny nose, cough, minor aches, and fever through H1 receptor antagonism, sigma-1 receptor agonism, NMDA receptor inhibition, and cyclooxygenase inhibition.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Coricidin.